首页> 外国专利> PAX2 AND PAX8 AS TUMOUR TARGETS FOR IMMUNOLOGIC AND MOLECULAR TREATMENT STRATEGIES

PAX2 AND PAX8 AS TUMOUR TARGETS FOR IMMUNOLOGIC AND MOLECULAR TREATMENT STRATEGIES

机译:PAX2和PAX8作为免疫和分子治疗策略的肿瘤靶标

摘要

Briefly, the present invention refers to the transcription factors PAX2 and PAX8 expressed in solid tumours and haematologic malignancies, and their utility as a target in immunotherapy and molecular therapy. In more detail, the invention refers to a method for identifying an immunogenic T-cell epitope from PAX2 and/or PAX8. Furthermore, the invention refers to a use of immunogenic T-cell epitopes, e.g. identified by said method, and their use as targets for the recognition by targeting means, e.g. T-cells or antibodies. The invention also refers to peptides representing immunogenic T-cell epitopes and their uses for the preparation of a pharmaceutical composition for immunotherapy of PAX2 and/or PAX8 expressing malignancies.
机译:简而言之,本发明涉及在实体瘤和血液系统恶性肿瘤中表达的转录因子PAX2和PAX8,及其在免疫治疗和分子治疗中的靶标用途。更详细地,本发明涉及从PAX2和/或PAX8中鉴定免疫原性T细胞表位的方法。此外,本发明涉及免疫原性T细胞表位的用途,例如T细胞抗原决定簇。通过所述方法识别,以及将其用作通过靶标手段识别的靶标,例如T细胞或抗体。本发明还涉及代表免疫原性T细胞表位的肽及其在制备用于免疫治疗表达PAX2和/或PAX8的恶性肿瘤的药物组合物中的用途。

著录项

  • 公开/公告号US2011015133A1

    专利类型

  • 公开/公告日2011-01-20

    原文格式PDF

  • 申请/专利权人 ULRICH KEILHOLZ;

    申请/专利号US20070377647

  • 发明设计人 ULRICH KEILHOLZ;

    申请日2007-08-20

  • 分类号A61K38/08;C07K7/06;G01N33/566;C12N5/0783;C07K16/18;A61P35;

  • 国家 US

  • 入库时间 2022-08-21 18:14:11

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号